Agios Pharmaceuticals, Inc. - Common Stock — Bilan (NASDAQ:AGIO)

Afficher le graphique complet Full chart

Financials

Total de l'actif 852.95 M1.44 B1.24 B937.12 M1.66 B1.3 B Total du passif 453.45 M145.76 M137.9 M126.1 M122.24 M104.11 M Total des capitaux propres 399.5 M1.29 B1.1 B811.02 M1.54 B1.19 B Total du passif et des capitaux propres 852.95 M1.44 B1.24 B937.12 M1.66 B1.3 B Dette totale —————— Dette nette ——————

Agios Pharmaceuticals, Inc. - Common Stock

Agios Pharmaceuticals Inc. is a publicly trading American pharmaceutical company pioneering therapies for genetically defined diseases, with a near-term focus on developing therapies for hemolytic anemias. The company was founded in 2008 by Lewis Cantley, Tak Mak and Craig Thompson. Agios is a Delaware corporation headquartered in Cambridge, Massachusetts. The company tendered an initial public offering in July 2013.

AGIO

Financials

Agios Pharmaceuticals, Inc. - Common Stock

Nouvelles

Agios: 'Sell' On Tebapivat Setback LR-MDS And Competitive PK Activator Drug Class (AGIO)

Why Is Agios Pharmaceuticals (AGIO) Up 8.6% Since Last Earnings Report?

Les actions Dell bondissent en prémarché ; Gap et Firefly Aerospace reculent

Agios abandonne le développement du tébapivat pour les troubles sanguins

L’action Agios Pharmaceuticals chute après un revers dans un essai clinique

AGIO's Pyrukynd Gets Approval for Thalassemia in Europe

L’UE approuve le mitapivat pour traiter la thalassémie chez l’adulte

Agios Seeks FDA Nod to Expand Mitapivat Label in Sickle Cell Disease

Agios présente les données sur le mitapivat au congrès européen d’hématologie

Agios dépose une demande pour le mitapivat dans la drépanocytose

AGIO Beats on Q1 Earnings & Sales, Stock Up 13% on New Drug Momentum

Agios Pharmaceuticals, Inc. (AGIO) Q1 2026 Earnings Call Transcript